IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
IMMUTEP Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Oct 24, 2025
$3.17−0.03 (-0.94%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2015 to 2025
Net margin
-594.6%−513.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +31.8% | +15.2% | -8.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -46.7% | -36.9% | |
| Return on assets | – | -30.9% | -34.3% | |
| Current ratio | – | 9.26 | 11.69 | |
| Capex to revenue | 1.3% | 0.1% | 0.4% | |
| Diluted shares | 235M | 413M | 1.46B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Immutep generated A$180.10M from operations and spent A$196.23K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
A$180.10M
Used
A$196.23K
Capital expenditureA$196.23K100%DividendsA$00%Share buybacksA$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-594.6%
×Asset turnover0.06×
×Equity multiplier1.08×
=Return on equity, FY2025-36.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -594.6% | 0.06× | 1.08× | -36.9% |
| FY2024 | -545.0% | 0.04× | 1.07× | -26.2% |
| FY2023 | -767.2% | 0.04× | 1.08× | -34.6% |
| FY2022 | -476.6% | 0.07× | 1.10× | -38.5% |
| FY2021 | -753.6% | 0.06× | 1.21× | -56.1% |
| FY2020 | -81.6% | 0.38× | 1.51× | -46.7% |
| FY2019 | -244.9% | 0.17× | 1.51× | -63.4% |
| FY2018 | -173.3% | 0.18× | 1.36× | -42.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-A$61.43M
- Cash generatingOperating cash flow above zero-A$62.05M
- Return on assets improvedROA up on the prior year-29.0% → -30.5%
- Earnings backed by cashOperating cash flow above net income-A$62.05M vs -A$61.43M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose18.25 → 11.69
- No dilutionShare count did not rise1.20B → 1.46B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.05 → 0.05